Skip to main content

Table 3 Probabilities of cost increase and decrease for patient groups, conditioned on drug groups and hospitalisation

From: Prediction of health care expenditure increase: how does pharmacotherapy contribute?

 

All

Hospitalisation

No Hospitalisation

N

P (Increase), %

N

P (Increase), %

N

P (Increase), %

Total study population (irrespective of drug groups)

373′264

51.9

66′427

23.1

306′837

58.1

Patients with drug group and highest probability of increase in costs

 ATC

Name

N

P (Increase), %

N

P (Increase), %

N

P (Increase), %

 N06DA

Anticholinesterases

2′214

61.1

587

43.4

1′627

67.4

 N04BA

Dopa and dopa derivatives

3′722

56.1

1′158

35.1

2′564

65.6

 B01AA

Vitamin K antagonists

18′893

51.6

6′087

27.0

12′806

63.2

 B03BB

Folic acid and derivatives

10′467

52.6

3′177

28.4

7′290

63.1

 C01BD

Antiarrhythmics, class III

4′622

47.3

1′890

25.7

2′732

62.3

 C03CA

Sulfonamides, plain

29′741

50.3

10′793

29.5

18′948

62.1

 B03AD

Iron in combination with folic acid

4′483

41.6

1′919

14.8

2′564

61.7

 C03BA

Sulfonamides, plain

3′256

52.7

961

31.2

2′295

61.7

 G04CB

Testosterone-5a-reductase inhibitors

2′238

53.2

552

27.5

1′686

61.6

 A10BB

Sulfonylureas

11′418

54.7

2′298

27.8

9′120

61.4

Patients with drug group and highest probability of decrease in costs

 ATC

Name

N

P (Decrease), %

N

P (Decrease), %

N

P (Decrease), %

 S01FA

Anticholinergics

2′959

72.4

626

78.9

2′333

70.7

 A03BA

Belladonna alkaloids, tertiary amines

7′851

73.4

1′964

82.1

5′887

70.5

 N01AH

Opioid anaesthetics

9′715

72.3

2′235

81.9

7′480

69.5

 S01HA

Local anaesthetics

7′783

71.5

1′598

79.3

6′185

69.5

 A04AA

Serotonin (5HT3) antagonists

3′771

70.9

1′637

77.3

2′134

66.0

 N01AX

Other general anaesthetics

29′106

68.2

7′299

80.3

21′807

64.1

 S01EC

Carbonic anhydrase inhibitors

9′510

66.7

2′120

79.7

7′390

63.0

 S01BC

Antiinflammatory agents, non-steroids

13′218

65.3

2′935

77.9

10′283

61.7

 C01CA

Adrenergic and dopaminergic agents

13′690

65.3

3′085

79.7

10′605

61.2

 A03BB

Belladonna alkaloids, semisynthetic

7′718

66.1

2′089

80.7

5′629

60.8

Patients with drug group, high probability of decrease in costs and frequent prescriptions

 ATC

Name

N

P (Decrease), %

N

P (Decrease), %

N

P (Decrease), %

 B05BB

Solutions affecting the electrolyte balance

66′792

64.0

20′392

77.9

46′400

58.0

 V08AB

Low osmolar X-ray contrast media*

29′654

63.7

10′870

78.1

18′784

55.3

 S01CA

Corticosteroids and antiinfectives in combination

28′050

59.7

5′774

78.0

22′276

55.0

 N01BB

Amides

57′144

59.6

14′887

77.0

42′257

53.5

  1. Bold data are considered table section headings. N = Number of patients per group (characterised by drug group and hospitalisation/no hospitalisation). P (Increase), P (Decrease) = Probability of cost increase or cost decrease in the respective group, displayed in %. The probability of increase in costs conditioned on hospitalisation was computed for all drug classes
  2. Selection criteria: 1.) prescribed to ≥1500 patients who didn’t have a hospitalisation, arranged by descending probability of increase or decrease (top 10 shown), 2.) prescribed to more than 10′000 patients who didn’t have a hospitalisation, arranged by descending probability of increase or decrease (top 4 not included in 1.) shown)
  3. ATC = “Anatomical Therapeutic Chemical” classification code, *Water-soluble, nephrotropic, low osmolar X-ray contrast media